Evidence map›Paper›PMID 40148747›Full record

ArticleCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2025

The International Trifecta

Matthias Raschpichler, Mohamed Abdel-Wahab, Nick Curzen, Manuel Wilbring, Christoph Dubois, Kayan Lam, Gloria Faerber, Jana Nagel, Holger Thiele, Michael A Borger

Registry-linked trialAbstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05389631 (The International Trifecta and Epic Valve-in-Valve Registry), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05389631 completednot on this map

The International Trifecta and Epic Valve-in-Valve Registry: Detailed Insights Into Management Strategies and Outcomes

TypeobservationalSponsorHelios Health Institute GmbHRan2022 to 2023Enrolled76ConditionsAortic Valve DiseaseArmsno intervention
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Matthias RaschpichlerLeipzig Heart Center, University Clinic of Cardiac Surgery, Leipzig, Germany.ORCID 0000-0003-0087-7972
Mohamed Abdel-WahabDepartment of Internal Medicine/Cardiology, Leipzig Heart Center, Leipzig, Germany.
Nick CurzenWessex Cardiothoracic Centre, University Hospital Southampton, Southampton, UK.
Manuel WilbringHeart Center Dresden, University Hospital Dresden, Dresden, Germany.
Christoph DuboisUniversity Hospital Leuven, Leuven, Belgium.
Kayan LamHeartcentre Catharina Hospital, Eindhoven, Netherlands.
Gloria FaerberUniversity Clinic of Cardiothoracic Surgery, Jena, Germany.
Jana NagelHelios Health Institute, Heart Center Leipzig, Leipzig, Germany.
Holger ThieleDepartment of Internal Medicine/Cardiology, Leipzig Heart Center, Leipzig, Germany.
Michael A BorgerLeipzig Heart Center, University Clinic of Cardiac Surgery, Leipzig, Germany.

Funding

Financial support was provided by the Abbott Structural Heart.
6 · The paper itself

Abstract

backgroundLittle is known about the clinical and hemodynamic outcome of valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) for failed Trifecta surgical aortic bioprotheses.

aimsWe aimed to compare outcomes of valve-in-valve transcatheter aortic valve replacement (ViV-TAVR into failed Trifecta

methodsData of consecutive patients who underwent ViV-TAVR into either failed Trifecta

resultsA total of 76 patients (49 Trifecta, 27 Epic) with a median age of 80 years (interquartile range [IQR] 75.0; 82.0]) and a median Society of Thoracic Surgeons-score of 5.4 (IQR 4.0; 9.8) were identified. Coronary protection techniques were more frequently performed in Trifecta than Epic patients (29.6% vs. 0%, p = 0.01). The primary composite outcome was observed in three Trifecta versus five Epic cases (6.1% vs. 20%, p = 0.1), which included one case of CO following ViV-TAVR into Epic requiring stenting. Increased rates of patient-prosthesis mismatch (PPM) following valve-in-Epic were found (41.7% vs. 75%, p = 0.08). Survival at a median of 365 days was 86.2% and did not differ between groups (log-rank p = 0.37).

conclusionsCompared to a stented prosthesis without increased risk of CO, ViV-TAVR into Trifecta prostheses can be performed with low risk of CO and acceptable short-term clinical outcomes. As the rate of post-ViV PPM is substantial for both prostheses, careful patient selection is warranted. (NCT05389631).

Indexed as

Aortic ValveAortic Valve StenosisBioprosthesisHeart Valve ProsthesisHemodynamicsProsthesis FailureTranscatheter Aortic Valve ReplacementAgedAged, 80 and overCoronary OcclusionFemaleHumansMaleProsthesis DesignRecovery of FunctionRegistriescoronary obstructionEpicTM‐valveexternally mounted leafletsTrifectaTM‐valvevalve‐in‐valve transcatheter aortic valve replacement

Identifiers

PMID40148747
PMCPMC12159376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.